Do you want to read an article? Please log in or register.
Sacituzumab Govitecan in mTNBC: Survival Benefit and Durable Disease Control Illustrated by a Case Report
Breast Cancer
SPECIAL REPORT
Related content
SABCS 2025
Breast Cancer
Sacituzumab govitecan shows clinically meaningful activity in real-world patients with metastatic TNBC and intracranial disease
CHICAGO 2026
Genitourinary Cancer
EV-302: The 3.5-year update shows that enfortumab vedotin plus pembrolizumab maintains durable survival benefit over chemotherapy in advanced urothelial carcinoma
SABCS 2025
Breast Cancer
ASCENT-03: Frontline sacituzumab govitecan improves QoL versus chemotherapy in patients with metastatic TNBC ineligible for PD-1/PD-L1 inhibitors
ESMO 2025
Breast Cancer
ASCENT-03: First-line sacituzumab govitecan improves PFS versus chemotherapy in patients with advanced TNBC ineligible for PD-1/PD-L1 inhibitors
Breast Cancer
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials
Lancet Oncol
Conforti F, Holtschmidt J, Nekljudova V, Sala I, Pagan E, Solbach C, Untch M, Denkert C, Bagnardi V, Pala L, Fasching PA, Schneeweiss A, Lück HJ, Viale G, De Pas T, van Mackelenbergh M, Huober J, Müller V, Link T, Karn T, Reinisch M, Marmé F, Bjelic-Radisic V, Schem C, Hartkopf A, Stickeler E, Hanusch C, Blohmer JU, Fehm T, Rhiem K, Gelber R, Loibl S
doi: 10.1016/S1470-2045(25)00546-7
ESMO 2025
Breast Cancer
ASCENT-04/KEYNOTE-D19: Sacituzumab govitecan plus pembrolizumab maintains QoL and delays functional decline in patients with PD-L1-positive metastatic TNBC
CHICAGO 2026
Genitourinary Cancer
ENGOT-EN6-NSGO/GOG-3031/RUBY: Post hoc analyses show sustained survival benefit with dostarlimab plus chemotherapy in dMMR/MSI-H endometrial cancer
CHICAGO 2026
Central Nervous System Tumors
ROADS: Cesium-131 tile-based radiation improves local control and survival in patients with resected brain metastases
RECOMMENDED
Breast Cancer
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
★ 3
Recommended by
Dr Andreas Müller, Faculty Member
N Engl J Med
Tolaney SM, de Azambuja E, Kalinsky K, Loi S, Kim SB, Yam C, Rapoport B, Im SA, Pistilli B, Mchayleh W, Cescon DW, Watanabe J, Bañuelas MAL, Freitas-Junior R, Salvador Bofill J, Afshari M, Gary D, Wang L, Lai C, Schmid P, ASCENT-04/KEYNOTE-D19 Clinical Trial Investigators
doi: 10.1056/NEJMoa2508959